Supriya Lifescience reported Q2 FY26 unaudited results with revenue of ₹199.83 crore, up 20.3% YoY; EBITDA ₹72.65 crore; PAT ₹50.43 crore; EPS ₹6.27, with EBITDA margin 36.4% and PAT margin 25.2%.
AI Assistant
Supriya Lifescience Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.